Response by Elliott et al to Letter Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy"

被引：1
|
作者：
Elliott, Perry [1 ]
Gundapaneni, Balarama [2 ]
Sultan, Marla B. [3 ]
机构：
[1] UCL, London, England
[2] Pfizer Inc, Groton, CT 06340 USA
[3] Pfizer Inc, New York, NY USA
来源：
CIRCULATION-HEART FAILURE | 2022年 / 15卷 / 07期
关键词：
D O I：
10.1161/CIRCHEARTFAILURE.122.009637
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Long-term Treatment with Inotersen for Amyloid Transthyretin Amyloidosis Cardiomyopathy
    Dasgupta, Noel
    Benson, Merrill
    JOURNAL OF CARDIAC FAILURE, 2018, 24 (08) : S59 - S59
  • [32] Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study
    Violaine Planté-Bordeneuve
    Farida Gorram
    Hayet Salhi
    Tarik Nordine
    Samar S. Ayache
    Philippe Le Corvoisier
    Daniel Azoulay
    Cyrille Feray
    Thibaud Damy
    Jean-Pascal Lefaucheur
    Journal of Neurology, 2017, 264 : 268 - 276
  • [33] GLOBAL LONGITUDINAL STRAIN AND DIASTOLOGY TO ASSESS TREATMENT RESPONSE TO TAFAMIDIS IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
    Tsai, Stacy
    Engstrom, Hayley
    Puglisi, Leah
    Mohan, Rajeev
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 458 - 458
  • [34] Long-Term Use of Tafamidis in Transthyretin Familial Amyloid Polyneuropathy: A Single Center Experience
    Coelho, Teresa
    Silva, Ana
    Maia, Luis
    Mandel, Francine
    Rosas, Gregory
    Karayal, Onur
    NEUROLOGY, 2013, 80
  • [35] Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study
    Plante-Bordeneuve, Violaine
    Gorram, Farida
    Salhi, Hayet
    Nordine, Tarik
    Ayache, Samar S.
    Le Corvoisier, Philippe
    Azoulay, Daniel
    Feray, Cyrille
    Damy, Thibaud
    Lefaucheur, Jean-Pascal
    JOURNAL OF NEUROLOGY, 2017, 264 (02) : 268 - 276
  • [36] Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
    Camille Vong
    Martin Boucher
    Steve Riley
    Lutz O. Harnisch
    American Journal of Cardiovascular Drugs, 2021, 21 : 535 - 543
  • [37] Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
    Vong, Camille
    Boucher, Martin
    Riley, Steve
    Harnisch, Lutz O.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2021, 21 (05) : 535 - 543
  • [38] Prognostic factors associated with survival in patients with wild-type transthyretin amyloid cardiomyopathy, treated with tafamidis
    Zemljic, G.
    Frljak, S.
    Poglajen, G.
    Zorz, N.
    Cerar, A.
    Okrajsek, R.
    Bajec, T.
    Vrtovec, B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 162 - 162
  • [39] Survival Benefit With Higher Dose Tafamidis in Patients With Hereditary and Wild-type Transthyretin Amyloid Cardiomyopathy
    Shah, Sanjiv J.
    Gundapaneni, Balarama
    Sultan, Marla B.
    Merlini, Giampaolo
    CIRCULATION, 2020, 142
  • [40] Letter by Sardu et al Regarding Article, "Persistent Long-Term Structural, Functional, and Metabolic Changes After Stress-Induced (Takotsubo) Cardiomyopathy"
    Sardu, Celestino
    Paolisso, Giuseppe
    Marfella, Raffaele
    CIRCULATION, 2018, 138 (09) : 954 - 955
12345